Positive clinical phase III results of vortioxetine in Japanese adults with Major Depressive Disorder
---------------------------------------------------------------------- · New clinical phase III data from a study conducted in Japan demonstrate the efficacy of vortioxetine compared to placebo for the treatment of Major Depressive Disorder (MDD) in Japanese adults · Positive results suggest that vortioxetine may be a potential treatment option for Japanese patients with MDD in the future · Based on the current data package, Lundbeck and Takeda intend to initiate the process for registration in Japan Valby, Denmark, and Osaka, Japan, 8 June 2018 - H. Lundbeck A/S (Lundbeck)